Sign In
Buy JAZZ
$240.06
+9.13 (+3.95%)
At Close: Jun 04, 2026
These are the new rules for investors who want to buy marijuana stocks
01:55pm, Saturday, 30'th Apr 2022 MarketWatch
The cannabis sector has had a big drawdown. The crash has several lessons for investors.
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
04:10pm, Friday, 29'th Apr 2022 Zacks Investment Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
01:33pm, Friday, 29'th Apr 2022
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q1 Earnings Expected to Decline
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This Stock Could Double Your Money in 2022
03:15pm, Friday, 22'nd Apr 2022 The Motley Fool
This biotech company may be on the verge of turning things around.
JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?
01:29pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.
Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
04:15pm, Wednesday, 20'th Apr 2022
DUBLIN , April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after the close
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon
02:49pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly
Why Axsome Therapeutics Is Jumping Higher on Tuesday
02:43pm, Tuesday, 19'th Apr 2022 The Motley Fool
A long-awaited FDA decision regarding AXS-05 finally has a timeline.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
10:20am, Friday, 15'th Apr 2022 Zacks Investment Research
Sector ETF report for XPH
3 Pot Stocks With Market Momentum
12:20pm, Thursday, 14'th Apr 2022 The Motley Fool
There are cannabis stocks that have seen their shares rise this year if you know where to look.
Looking For Long Term Cannabis Stocks To Buy? Top Marijuana Stocks To Invest In 2022
02:00pm, Tuesday, 12'th Apr 2022
Top Medical Marijuana Stocks To Invest In For 2022 The post Looking For Long Term Cannabis Stocks To Buy? Top Marijuana Stocks To Invest In 2022 appeared first on Marijuana Stocks | Cannabis Investmen
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
06:29pm, Friday, 08'th Apr 2022 Zacks Investment Research
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
03:48pm, Friday, 08'th Apr 2022
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
Forget GameStop and AMC: Buy These 2 Growth Stocks Instead
02:15pm, Thursday, 07'th Apr 2022 The Motley Fool
Unlike with many meme stocks, there are some solid fundamentals behind these investments.
